Company Filing History:
Years Active: 2011-2012
Title: Lynnetta Watts: Innovator in Kidney Targeting Technologies
Introduction
Lynnetta Watts is a prominent inventor based in Carlsbad, CA (US). She has made significant contributions to the field of biomedical research, particularly in the development of antisense oligonucleotides for kidney targeting. With a total of 3 patents to her name, her work has the potential to impact the treatment of various kidney-related diseases.
Latest Patents
One of her latest patents focuses on "Antisense oligonucleotides optimized for kidney targeting." This invention provides antisense compounds and methods for modulating the expression of target genes expressed in the kidney. Specifically, it offers antisense oligonucleotide compounds optimized for targeting nucleic acid molecules expressed in the kidney. These compounds have been shown to efficiently modulate the expression of target genes such as SGLT2 and connective tissue growth factor (CTGF) in the kidney. Another significant patent involves the modulation of SGLT2 expression, where compounds, compositions, and methods are provided for modulating the expression of SGLT2. The compositions comprise oligonucleotides targeted to nucleic acid encoding SGLT2, with methods for using these compounds for diagnosis and treatment of diseases associated with SGLT2 expression.
Career Highlights
Lynnetta Watts has established herself as a key figure in her field through her innovative research and development efforts. She is currently associated with Isis Pharmaceuticals, Inc., where she continues to advance her work in kidney-targeting technologies.
Collaborations
Throughout her career, Lynnetta has collaborated with notable professionals in her field, including Andrew M Siwkowski and Edward Wancewicz. These collaborations have further enriched her research and contributed to her success as an inventor.
Conclusion
Lynnetta Watts is a trailblazer in the field of kidney-targeting technologies, with a focus on antisense oligonucleotides. Her innovative patents and collaborations highlight her commitment to advancing medical science and improving patient outcomes.